Relay Therapeutics announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its lead PI3Kα inhibitor, zovegalisib (RLY‑2608), in combination with fulvestrant for patients with hormone‑receptor positive, HER2‑negative metastatic breast cancer who have progressed after CDK4/6 inhibition and carry PIK3CA mutations.
The designation was based on interim data from the Phase 1/2 ReDiscover trial. 118 patients were enrolled across two dosing cohorts—52 patients on the fasted 400 mg twice‑daily dose and 57 patients on the fed 400 mg twice‑daily dose. The overall median progression‑free survival was 10.3 months, while second‑line patients achieved 11.4 months. The safety profile was favorable, with no new safety signals and a manageable incidence of hyperglycemia and rash.
The FDA’s Breakthrough Therapy designation allows Relay to receive accelerated guidance, priority review, and enhanced interaction with regulators, potentially shortening the path to market approval. The designation also signals regulatory confidence in the drug’s clinical benefit and may improve investor perception of the company’s pipeline.
Zovegalisib’s mutant‑selective, allosteric mechanism differentiates it from broader PI3K inhibitors that have struggled with toxicity. By targeting mutant PI3Kα, the drug aims to reduce hyperglycemia and rash, addressing a key unmet need in a population where approximately 40 % of HR+/HER2‑negative metastatic breast cancers harbor PIK3CA mutations. The drug also has potential applications in PI3Kα‑driven vascular anomalies, expanding its market opportunity.
Relay’s cash position stands at $596 million, funding operations through 2029, and the company has delivered strong stock performance—an 82 % return over the past year and a 143 % gain in the last six months. Analyst upgrades, including Oppenheimer’s “Outperform” rating and a $14 price target, have reinforced market confidence. President of R&D Don Bergstrom noted that the designation “underscores the FDA’s recognition of the potential of zovegalisib in combination with fulvestrant to meaningfully improve outcomes for these patients.”
The next key milestone is the topline data from the Phase 3 ReDiscover‑2 trial, expected in mid‑2026. Positive results could lead to a launch in the U.S. and potentially other markets, while the company continues to develop other pipeline candidates and explore additional indications for zovegalisib.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.